Format
Sort by

Send to

Choose Destination

Search results

Items: 8

1.

Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity.

Patti F, Messina S, Solaro C, Amato MP, Bergamaschi R, Bonavita S, Bruno Bossio R, Brescia Morra V, Costantino GF, Cavalla P, Centonze D, Comi G, Cottone S, Danni M, Francia A, Gajofatto A, Gasperini C, Ghezzi A, Iudice A, Lus G, Maniscalco GT, Marrosu MG, Matta M, Mirabella M, Montanari E, Pozzilli C, Rovaris M, Sessa E, Spitaleri D, Trojano M, Valentino P, Zappia M; SA.FE. study group..

J Neurol Neurosurg Psychiatry. 2016 Sep;87(9):944-51. doi: 10.1136/jnnp-2015-312591.

2.

Natalizumab in the pediatric MS population: results of the Italian registry.

Ghezzi A, Moiola L, Pozzilli C, Brescia-Morra V, Gallo P, Grimaldi LM, Filippi M, G GC; MS Study Group-Italian Society of Neurology..

BMC Neurol. 2015 Sep 25;15:174. doi: 10.1186/s12883-015-0433-y.

3.

Lesion load may predict long-term cognitive dysfunction in multiple sclerosis patients.

Patti F, De Stefano M, Lavorgna L, Messina S, Chisari CG, Ippolito D, Lanzillo R, Vacchiano V, Realmuto S, Valentino P, Coniglio G, Buccafusca M, Paolicelli D, D'Ambrosio A, Montella P, Brescia Morra V, Savettieri G, Alfano B, Gallo A, Simone I, Viterbo R, Zappia M, Bonavita S, Tedeschi G.

PLoS One. 2015 Mar 27;10(3):e0120754. doi: 10.1371/journal.pone.0120754.

4.

JC virus antibody index in natalizumab-treated patients: correlations with John Cunningham virus DNA and C-reactive protein level.

Lanzillo R, Liuzzi R, Vallefuoco L, Moccia M, Amato L, Vacca G, Vacchiano V, Portella G, Brescia Morra V.

Ther Clin Risk Manag. 2014 Oct 9;10:807-14. doi: 10.2147/TCRM.S63295.

5.

Chronic cerebrospinal venous insufficiency in multiple sclerosis: a highly prevalent age-dependent phenomenon.

Lanzillo R, Mancini M, Liuzzi R, Di Donato O, Salvatore E, Maglio V, Vacca G, Amato L, D'Anna G, Brunetti A, Brescia Morra V.

BMC Neurol. 2013 Feb 13;13:20. doi: 10.1186/1471-2377-13-20.

6.

Antiphospholipid-related chorea.

Peluso S, Antenora A, De Rosa A, Roca A, Maddaluno G, Brescia Morra V, De Michele G.

Front Neurol. 2012 Oct 22;3:150. doi: 10.3389/fneur.2012.00150.

7.

Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study.

Lugaresi A, Florio C, Brescia-Morra V, Cottone S, Bellantonio P, Clerico M, Centonze D, Uccelli A, di Ioia M, De Luca G, Marcellusi A, Paolillo A; BRIDGE study group..

BMC Neurol. 2012 Mar 5;12:7. doi: 10.1186/1471-2377-12-7.

8.

A combined nucleic acid and protein analysis in Friedreich ataxia: implications for diagnosis, pathogenesis and clinical trial design.

Saccà F, Puorro G, Antenora A, Marsili A, Denaro A, Piro R, Sorrentino P, Pane C, Tessa A, Brescia Morra V, Cocozza S, De Michele G, Santorelli FM, Filla A.

PLoS One. 2011 Mar 11;6(3):e17627. doi: 10.1371/journal.pone.0017627.

Items per page

Supplemental Content

Loading ...
Support Center